Completed PHASE3 INTERVENTIONAL 2-arm NCT01710696

Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome

Induction of Puberty With 17-Beta Estradiol in Girls With Turner Syndrome. An Open Randomized Trial

Sponsor: Novo Nordisk A/S

Conditions Genetic Disorder Turner Syndrome

Updated 8 times since 2017 Last updated: Feb 27, 2017 Started: Jul 23, 1998 Primary completion: Jul 26, 2004 Completion: Jul 26, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Genetic Disorder and Turner Syndrome and is currently completed. Novo Nordisk A/S leads this study, which shows 8 recorded versions since 1998 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Mar 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Badajoz, Spain , Barakaldo, Spain , Cáceres, Spain , Córdoba, Spain , El Palmar, Spain , Elche, Spain , Esplugues Llobregat, Spain , Granada, Spain , Jaén, Spain and 13 more locations